0000950103-16-014334.txt : 20160624
0000950103-16-014334.hdr.sgml : 20160624
20160624144404
ACCESSION NUMBER: 0000950103-16-014334
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160624
FILED AS OF DATE: 20160624
DATE AS OF CHANGE: 20160624
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Anacor Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001411158
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 251854385
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1020 E. MEADOW CIRCLE
CITY: PALO ALTO
STATE: CA
ZIP: 94303
BUSINESS PHONE: 650-543-7500
MAIL ADDRESS:
STREET 1: 1020 E. MEADOW CIRCLE
CITY: PALO ALTO
STATE: CA
ZIP: 94303
FORMER COMPANY:
FORMER CONFORMED NAME: Anacor Pharmaceuticals Inc
DATE OF NAME CHANGE: 20070830
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bell Graeme
CENTRAL INDEX KEY: 0001643757
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34973
FILM NUMBER: 161730779
MAIL ADDRESS:
STREET 1: 1324 WAVERLY ROAD
CITY: GLADWYNE
STATE: PA
ZIP: 19035
4
1
dp66701_4-bell.xml
FORM 4
X0306
4
2016-06-24
1
0001411158
Anacor Pharmaceuticals, Inc.
ANAC
0001643757
Bell Graeme
C/O ANACOR PHARMACEUTICALS, INC.
1020 EAST MEADOW CIRCLE
PALO ALTO
CA
94303
0
1
0
0
Executive VP and CFO
Common Stock
2016-06-24
4
D
0
10488
99.25
D
0
D
Performance Restricted Stock Units
2016-06-24
4
D
0
8008
D
Common Stock
8008
0
D
Performance Restricted Stock Units
2016-06-24
4
D
0
4004
D
Common Stock
4004
0
D
Performance Restricted Stock Units
2016-06-24
4
D
0
5000
D
Common Stock
5000
0
D
Stock Option (right to buy)
69.34
2016-06-24
4
D
0
28793
D
Common Stock
28793
0
D
Stock Option (right to buy)
78.91
2016-06-24
4
D
0
25299
D
Common Stock
25299
0
D
As of the effective time of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 14, 2016 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Quattro Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, pursuant to the terms of the Merger Agreement, (i) each share of the Issuer's Common Stock held by the reporting person was disposed of in exchange for the merger consideration of $99.25 per share, (ii) each award of restricted stock units (including performance restricted stock units) and stock options became fully vested and (iii) each award of restricted stock units (including performance restricted stock units) and stock options was cancelled in exchange for the right to receive a cash payment per share in an amount equal to $99.25 less, in the case of stock options, the applicable exercise price.
Includes shares acquired pursuant to the Issuer's ESPP since the reporting person's last Form 4.
/s/ Lucy O. Day, Attorney-in-fact
2016-06-24